E. coli Nissle 1917 in the treatment of Inflammatory Bowel Disease

Practical Gastroenterology

Volumn 34, Issue 3, 2010, Pages 11-19

  Schultz, Michael ^a   Butt, Grant ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PREDNISOLONE; PROBIOTIC AGENT;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG SAFETY; ENTERITIS; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; INTESTINE MUCOSA; MICROFLORA; NONHUMAN; ULCERATIVE COLITIS;

EID: 77953566879     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Nissle A. Ueber die Grundlagen einer neuen ursaechlichen Bekaempfung der pathologischen Darmflora (On the fundamentals for new causal control of pathological intestinal microflora). Dt Med Wschr, 1916;42:1181-1184.
2. Wolf KM. Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli. Clin Microbiol Rev, 1997;10:569-584.
3. Blum G, Marre R, Hacker J. Properties of Escherichia coli strains of serotype O6. Infection, 1995;23:234-236.
4. Grozdanov L, Zahringer U, Blum-Oehler G, et al. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol, 2002;184:5912-5925.
5. Grozdanov L, Raasch C, Schulze U, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol, 2004;186:5432-5441.
6. Nagy G, Dobrindt U, Grozdanov L, et al. Transcriptional regulation through RfaH contributes to intestinal colonization by Escherichia coli. FEMS Microbiol Lett, 2005;244:173-180.
7. Blum-Oehler G, Oswald S, Eiteljorge K, et al. Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol, 2003;154:59-66.
8. Valdebenito M, Crumbliss AL, Winkelmann G, et al. Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. Int J Med Microbiol, 2006;296:513-520.
9. Grosse C, Scherer J, Koch D, et al. A new ferrous iron-uptake transporter, EfeU (YcdN), from Escherichia coli. Mol Microbiol, 2006;62:120-131.
10. Sun J, Gunzer F, Westendorf AM, et al. Genomic precularity of coding sequenzes and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data. J Biotech, 2005;117:147-161.
11. Papavassiliou J. Production of Colicines in Simmons's Citrate Agar. Nature, 1959;184:1339-1340.
12. Nissle A. Die antagonistische Behandlung chronischer Darmstoerungen mit Colibakterien (The antagonistical therapy of chronic intestinal disturbances). Med Klinik, 1918:29-30.
13. Papavassiliou J. Biological Characteristics of Colicine X. Nature, 1961;190:110.
14. Patzer SI, Baquero MR, Bravo D, et al. The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology, 2003;149:2557-2570.
15. Schultz M, Watzl S, Oelschlaeger TA, et al. Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle (EcN) in vivo. J Microbiol Meth, 2005;61:389-398.
16. Prilassnig M, Wenisch C, Daxboeck F, et al. Are probiotics detectable in human feces after oral uptake by healthy volunteers? Wien Klin Wochenschr, 2007;119:456-462.
17. Wietersheim v J, Kessler H. Psychotherapy with chronic inflammatory bowel disease patients: a review. Inflamm Bowel Dis 2006;12:1175-1184.
18. Loftus VE. Clinical Epidemiology of Inflammatory Bowel Disease: Incidence, Prevalence, and Environmental Influences. Gastroenterology, 2004;126:1504-1517.
19. Sartor BR. Microbial influences in inflammatory bowel diseases. Gastroenterology, 2008;134:577-594.
20. Kokesova A, Frolova L, Kverka M, et al. Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia microbiologica, 2006;51:478-484.
21. Schultz M, Strauch UG, Linde HJ, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol, 2004;11:372-378.
22. Kamada N, Inoue N, Hisamatsu T, et al. Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis, 2005;11:455-463.
23. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol, 1997;25:653-658.
24. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther, 1997;11:853-858.
25. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet, 1999;354:635.
26. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004;53:1617-1623.
27. Henker J, Laass M, Blokhin BM, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Ped Infect Dis J, 2008;27:494-499.
28. Hoffmann JC, Zeitz M, Bischoff CS, et al. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German Society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease. Z Gastroenterol, 2004;42:979-983.
29. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature, 2007;448:427-434.
30. Schlee M, Wehkamp J, Altenhoefer A, et al. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun, 2007;75:2399-2407.
31. Wehkamp J, Harder J, Wehkamp B, et al. NF-kappaB- and AP-1- mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun, 2004;72:5750-5758.
32. Zyrek AA, Cichon C, Helms S, et al. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol, 2007;9:804-816.
33. Sturm A, Rilling K, Baumgartner DC, et al. Escherichia coli Nissle 1917 distinctively modulates T cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun, 2005;73:1452-1465.
34. Helwig U, Lammers KM, Rizzello F, et al. Lactobacilli, bifidobacteria and E. coli Nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol, 2006;12:5978-5986.
35. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol, 2004;286:G613-626.
36. Altenhoefer A, Oswald S, Sonnenborn U, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cels by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol, 2004;40:223-229.
37. Boudeau J, Glasser LA, Julien S, et al. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther, 2003;18:45-56.
38. Mandel L, Trebichavsky I, Splichal I, et al. Stimulation of intestinal immune cells by E. coli in gnotobiotic piglets. In: Mestecky, J., eds. Advances in Mucosal Immunology. New York: Plenum Press; 1995:463-464.
39. Lorenz A, Schulze J. Establishment of E. coli Nissle 1917 and its interaction with Candida albicans in gnotobiotic rats. Microecology and Therapy, 1996;24:45-51.
40. Besselink MG, v Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet, 2008;371:651-659.
41. Krammer HJ, Kamper H, v Bunau R, et al. [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients]. Z Gastroenterol, 2006;44:651-656.
42. Rohrenbach J, Matthess A, Meier R, et al. Escherichia coli Stamm Nissle 1917 (EcN) bei Kindern (E. coli Nissle 1917 in children). Kinder- und Jugendarzt, 2007;38:1-5.
43. Schultz M, Lindstroem AL. Rationale for probiotic treatment strategies in inflammatory bowel disease. Exp Rev Gastroenterol Hepatol, 2008;2:337-355.
44. Plassmann D, Schulte-Witte H. [Treatment of Irritable Bowel Syndrome with Escherichia coli Strain Nissle 1917 (EcN). A Retrospective Survey.]. Med Klin (Munich), 2007;102:888-892.
45. Rasche C, Wolfram C, Wahls M, et al. Differential immunomodulating effects of inactivated probiotic bacteria on the allergic immune response. Acta dermato-venereologica, 2007;87:305-311.
46. Kuzela L, Kascak M, Vavrecka A. Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol, 2001;96:3218-3219.